Ipsen

Ipsen Assets per Share

The Total Assets per Share of Ipsen (IPN.PA) as of Oct 9, 2026 is 83.22 EUR. In the previous year, Total Assets per Share was 77.24 EUR — a change of 7.75% (higher).

Assets per Share

83.22EUR

YoY

7.75%

Last updated:

Total Assets per Share of Ipsen is 2025 83.22 EUR. Total Assets per Share of Ipsen was 2024 77.24 EUR. It decreases by 7.75% higher compared to the previous year.

The Ipsen Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
40.51 EUR
Jan 1, 2019
51.66 EUR
Jan 1, 2020
51.74 EUR
Jan 1, 2021
59.86 EUR
Jan 1, 2022
67.27 EUR
Jan 1, 2023
75.85 EUR
Jan 1, 2024
77.24 EUR
Jan 1, 2025
83.22 EUR
The Ipsen Assets per Share history
YEARAssets per ShareYoY
83.22EUR+7.75%
77.24EUR+1.84%
75.85EUR+12.75%
67.27EUR+12.37%
59.86EUR+15.71%
51.74EUR+0.14%
51.66EUR+27.52%
40.51EUR+9.94%
36.85EUR+26.76%
29.07EUR+25.05%
23.25EUR+13.12%
20.55EUR—
Access this data via the Eulerpool API

Ipsen Stock analysis

What does Ipsen do? Ipsen SA is a French biopharmaceutical company specialized in the development of drugs for the treatment of cancer, neurological disorders, and endocrine disorders. It was founded in 1929 by a pharmacist named Henri Beaufour and is headquartered in Paris. The history of Ipsen began with the production of extraction products from snake venom for the manufacturing of serum against tetanus and diphtheria. In the 1960s, the company started to focus on the production of hormones and peptides, with a focus on endocrine disorders. In the 1990s, Ipsen expanded its product portfolio to include oncology and neurological disorders. Ipsen's business model focuses on research and development of new drugs, as well as marketing of already established drugs in selected markets worldwide. The company employs around 5,700 employees and operates in more than 115 countries. Ipsen has two main business segments: specialty drugs and consumer healthcare. The specialty drugs segment focuses on the development and marketing of innovative therapies in the areas of oncology, endocrinology, and neuroscience. Ipsen's most well-known products include Somatuline, a drug for the treatment of acromegaly, and Decapeptyl, a drug for the treatment of prostate cancer and endometriosis. In the consumer healthcare segment, Ipsen is mainly specialized in the production of drugs for the treatment of gastrointestinal disorders and cold and flu symptoms. Some well-known brands include Smecta, a drug for diarrhea, and Nurofen, a pain reliever. Ipsen also has a strong presence in the field of aesthetic medicine, where the company operates a subsidiary called Ipsen Aesthetic. This subsidiary develops and markets products for the treatment of wrinkles and other signs of aging on the skin. Well-known brands of Ipsen Aesthetic include Dysport, a botulinum toxin product for the treatment of wrinkles, and the filler Restylane. Overall, Ipsen has established itself as a leading biopharmaceutical company focused on the development and marketing of products in specialized therapy areas. The company has a strong pipeline of new products in development and remains an important player in the pharmaceutical industry due to its strong scientific expertise and global presence. Ipsen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ipsen stock

Total Assets per Share of Ipsen is 83.22 EUR in 2025.

Total Assets per Share of Ipsen changed from 77.24 EUR to 83.22 EUR, representing a 7.75% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Ipsen since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

Other — Ipsen

All Key Metrics — Ipsen